High-Dose Ascorbic Acid
High Dose Ascorbic Acid for Plasma Cell Disorders
What's the purpose of the trial?
This is a Phase I single-arm open-label clinical study primarily assessing the safety and secondarily, the relative efficacy of low dose melphalan + high dose ascorbate acid (HDAA) in relapsed refractory patients with multiple myeloma.
Accepting patients
Participating Centers
There is one center participating in this trial. Enter a location below to view the distance.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Melphalan is a chemotherapy medication used in the treatment of different cancers.
- Vitamin C is an antioxidant that is found in many different kinds of foods. Researchers are studying whether high doses of Vitamin C may help cancer medications to work more effectively.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.